Conflicting evidence exists regarding the association between warfarin treatment, death, and ischemic stroke incidence in patients with advanced chronic kidney disease (CKD) and atrial fibrillation.
as renal function deteriorates. Embolism from the heart is a major cause of ischemic stroke, particularly in atrial fibrillation. Patients with concomitant atrial fibrillation and reduced kidney function are increasingly common, not only because both conditions share common risk factors, but also because they promote one another. 3, 4 Not unexpectedly, patients with CKD and atrial fibrillation have higher risk of ischemic stroke and thrombembolism than patients without CKD. 5, 6 Anticoagulation therapies, such as warfarin, are indicated in most patients with atrial fibrillation and supported by prospective, randomized trials demonstrating a marked efficacy. Although such trials have excluded individuals with renal dysfunction, the use of anticoagulation has also been extended to patients with CKD. However, in recent years, observational studies suggest that the use of warfarin may actually increase the risk of death and stroke among such patients. [7] [8] [9] On the other hand, other reports show no increased risk in patients with hemodialysis who are treated with warfarin and patients with CKD and atrial fibrillation. [10] [11] [12] This conflicting evidence allows no clear recommendation regarding the use of warfarin in patients with CKD, despite their high risk of stroke. Further, it is unknown whether there is a level of renal dysfunction at which the risk may outweigh the benefit. The objective of this study was to investigate outcomes associated with warfarin treatment in relation to kidney function among patients with established cardiovascular disease and atrial fibrillation (ie, a group of patients having a strong rationale for anticoagulation therapy according to the CHA 2 DS 2 -VASc score for atrial fibrillation stroke risk criteria).
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Methods
Patient Population
All patients were informed about their participation in the registry and the follow-up and had the right to refuse. The registry and the merging of registries were approved by The National Board of Health and Welfare and the ethics committee at Karolinska Institutet, Stockholm. We used data from 2003 to 2010 from the nationwide Swedish WebSystem for Enhancement and Development of EvidenceBased Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry. This registry includes all Swedish hospitals (N = 72) that provide care for acute cardiac diseases, and enrolls all consecutive patients admitted to a coronary care unit with symptoms suggestive of an acute coronary syndrome. 15 
Clinical Characteristics
Previous history of diabetes mellitus, hypertension, myocardial infarction, heart failure, peripheral vascular disease, atrial fibrillation, ischemic stroke, hemorrhagic stroke, other bleeding, chronic obstructive pulmonary disease, dementia, or cancer were obtained from the SWEDEHEART registry form and enriched with data linkages to the National Inpatient Registry, which includes diagnoses for all patients hospitalized in Sweden since 1987 to December 31, 2011 (eTable 1 in the Supplement). Information on patient presentation at admission, hospital course variables, and medication at admission and discharge were also collected. Atrial fibrillation was defined as a history of atrial fibrillation, electrocardiography showing signs of atrial fibrillation, or both, either on admission or during the in-hospital course. The majority of creatinine assessments were performed by either enzymatic or corrected Jaffe method (alkaline picrate reaction), both of which are traceable to isotope dilution mass spectroscopy standards. For creatinine measurements performed with non-isotope dilution mass spectroscopy-traceable methods, values were reduced by 5% prior to being entered into the CKD-EPI formula. 17, 18 On the basis of current International 
Renal Function Assessment
Definition of Exposure and Outcomes
The exposure was prescription of warfarin at discharge as registered in SWEDEHEART. No information on warfarin dosages was available. Mortality data were obtained by data linkages to the Swedish population registry, which included information about the vital status of all Swedish citizens through December 31, 2011. Hospitalizations during follow-up due to myocardial infarction, ischemic stroke, or bleeding were obtained from the National Inpatient Registry. Bleeding was defined as readmission due to hemorrhagic stroke, gastrointestinal bleeding, bleeding causing anemia, and others. Outcome definitions are further expanded in eTable 2 in the Supplement.
The following outcomes were defined a priori: (1) the composite outcome of death, readmission due to myocardial infarction and ischemic stroke within 1 year from discharge date, (2) readmission because of bleeding within 1 year from discharge date, and (3) the aggregate of these 2 outcomes. For these composite end points, the earliest (if any) event was selected. When analyzing separate end points, patients were censored for death. No other censoring was applied. R package's Multivariate Imputation by Chained Equations (MICE) was used to form 20 imputed data sets.
Warfarin use vs no warfarin use was considered as a time-fixed binary variable throughout the follow-up period. Event rates for the study outcomes were calculated for each renal dysfunction category, reporting crude risk ratios. The association between warfarin and outcomes was studied by Cox proportional hazard models. Two sets of multivariable models were investigated to study the effect of potential confounders: (1) adjustment for age (5-knot restricted cubic spline), sex, eGFR, preexisting comorbidities (diabetes mellitus, hypertension, myocardial infarction, chronic heart failure, peripheral vascular disease, ischemic stroke, bleeding, chronic obstructive pulmonary disease, and cancer within 3 years), patient presentation characteristics at admission (ST segment elevation myocardial infarction [STEMI] and decompensated heart failure [Killip class ≥2]), hospital course (percutaneous coronary intervention and coronary artery bypass graft), discharge medication (antiplatelet therapy [none, mono, or dual]), β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins), and center effect (as a random effect via a γ frailty distribution); and, in a separate model, (2) we further adjusted for left ventricular ejection fraction due to the large amount of imputed data for this variable. Inverse-variance-weighted linear regression was used to assess linear trends across eGFR categories (using equidistant CKD stages) on studied outcomes. Time to event (cumulative incidence) Kaplan-Meier curves were plotted across CKD stages with and without warfarin treatment.
Two sensitivity analyses were performed: to assess the effect of imputation, we (1) ran a complete-case analysis for the adjusted model (there were 23 056 such patients, corresponding to 94.8% of the total study population); and to assess the effect of confounding by indication, (2) propensity scores were calculated using random-effects logistic regression models with warfarin at discharge as the outcome and all variables of the primary analysis model as explanatory variables. 21 Patients were then matched on estimated propensity scores using full matching 22 via the R package's Optmatch. A caliper of 0.01 was used, except for the patient category of eGFR ≤15 , where this led to many unmatched patients. For this stratum, a caliper of 0.02 was used instead. The analysis was then done as a Cox regression with warfarin at discharge as a predictor, and the matching indicator as a random effect using a γ frailty model. In a final step, subgroup analyses were performed to assess the robustness of our results. Not all of these models could be run successfully due to (1) no warfarin contrast (no contrast in the exposure), (2) too few events (strata with <10 events), and (3) the model failed to converge. When this occurred it is indicated in the corresponding tables.
Results
Between 2003 and 2010, a total of 158 059 individuals were admitted with an acute myocardial infarction. Atrial fibrillation was found in 34 087 individuals. Patients were excluded if they lacked information on serum creatinine (n = 2351), warfarin treatment (n = 357), or age (n = 2). They were also excluded if they died before hospital discharge (n = 2580), had been registered in SWEDEHEART previously (n = 4367) or because of registration errors (n = 113). A patient flowchart is illustrated in eFigure 1 in the Supplement.
Patient Characteristics
The remaining 24 317 patients were included in the analysis and 21.8% of these were prescribed warfarin at discharge. Table 1 and Table 2 summarize baseline characteristics of included patients stratified by warfarin treatment. Patients treated with warfarin did not differ from patients receiving no warfarin with regard to basic demographics. However, several comorbidities, such as heart failure, diabetes, and ischemic stroke, were more common in individuals treated with warfarin. In both groups, the CHADS 2 score was 2 or higher in the majority of patients. Clinical history of hemorrhagic stroke and bleeding seemed more frequent among patients who did not receive warfarin at discharge. There was a similar rate of patient inclusion during the different admission years.
As many as 51.7% of patients were considered to have CKD stage 3 or higher, with an eGFR higher than 60 mL/min/ 1.73 m 2 . Of these, 41.7% of patients had CKD stage 3, 8.1% had CKD stage 4, and 2.0% had CKD stage 5. eTable 3 in the Supplement shows patient characteristics according to CKD stages and warfarin treatment. As CKD categories increased in severity, patients tended to be older and less often smokers. The prevalence of comorbid diabetes, hypertension, cardiovascular disease (myocardial infarction, chronic heart failure, peripheral vascular disease, and ischemic stroke), as well as the number of patients with a CHADS 2 score of 2 or higher increased with the worsening of CKD stages. Patients with CKD also presented more severe symptoms, such as heart failure (Killip class ≥2), at admission, but the number of patients presenting with STEMI and the proportion of percutaneous coronary interventions performed decreased. Dual antiplatelet therapy and statin treatment at discharge seemed less common across worsening CKD stages, but the proportion of patients receiving calcium antagonists or diuretics tended to increase. Patients with CKD stage 5 were less often prescribed warfarin (13.8%) compared with other categories (eGFR >60 , 22.0%; eGFR >30-60 , 22.4%; eGFR >15-30 , 18.9%). In all CKD strata, patients receiving warfarin more often had a history of heart failure, ischemic stroke, and diabetes, as well as a higher CHADS 2 score. History of hemorrhagic stroke or prior bleeding tended to be less common among patients treated with warfarin across the different CKD strata.
Outcome Analyses
The number of patients who developed the composite outcome, bleeding events, and the aggregate of these 2 out-comes increased with the worsening of CKD categories (Table 3) , as did the rate at which these events occurred (Table 3, Figure 1 [panels A and C], and Figure 2 [ Figure 1, panel D) . Regardless of CKD stage, the number of deaths was lower in patients treated with warfarin compared with patients receiving no warfarin. The rate of readmissions due to myocardial infarction and ischemic strokes were lower in the patients treated with warfarin across all renal function strata. . The magnitude of the association between warfarin treatment and outcomes was little modified by multivariable adjustment, and no linear trends were observed across strata. Similar results for the primary analysis were observed in complete-case analyses or propensity score-matching. Information on the performance of the propensity score-matching and the balance between variables in warfarin-exposed and nonexposed individuals is shown in eTable 4 through eTable 9 in the Supplement.
Subgroup Analyses
Several subgroup analyses were undertaken to study the robustness of our findings (eTable 10 and eTable 11 in the Supplement). Similar results for the primary analysis were found for the composite outcome of death, myocardial infarction, and ischemic stroke, and the same was true when further considering bleeding risk as an aggregate. The low number of bleeding events in the subgroup populations limits drawing solid conclusions and these analyses were not performed.
Discussion
Recent observational studies have prompted concern about the value of warfarin anticoagulation in CKD stage 5 or dialysis patients with atrial fibrillation. In these studies, warfarin treatment was associated with an increased risk of stroke, death, or both, [7] [8] [9] resulting in modification of current guidelines, which call for caution regarding warfarin use in this patient group. 23 Our study addressed this issue in a large cohort of consecutive patients with myocardial infarction, atrial fibrillation, and varying severity of CKD. We report that warfarin treatment was associated with a lower 1-year risk of the composite end point of death, myocardial infarction, and ischemic stroke without a higher risk of bleeding. This association was observed in patient strata with moderate, severe, or end-stage CKD. Our finding partially accords with the recent study by Olesen and coauthors 12 from Denmark, where warfarin treatment was associated with a lower risk of stroke or thromboembolism in patients with atrial fibrillation irrespective of their renal function. Compared with that study, our analysis may offer some advantages, as we estimated renal function by eGFR rather than International Classification of Diseases codes for renal replacement therapy initiation. The use of International Classification of Diseases codes probably underestimates CKD prevalence 24 and also offers no possibility to assess risks associated with impaired renal function prior to renal replacement therapy. In addition, we expand to a nationally representative sample of high-risk individuals that virtually all have . b Adjusted models considered multivariate adjustment for age, sex, center, eGFR, preexisting comorbidities (diabetes mellitus, hypertension, myocardial infarction, congestive heart failure, cerebrovascular disease, ischemic stroke, bleeding, chronic obstructive pulmonary disease, cancer, and atrial fibrillation), patient presentation characteristics at admission (ST-segment elevation myocardial infarction, Killip Ն2), hospital course (percutaneous coronary intervention and coronary artery bypass graft surgery), and discharge medication (antiplatelet therapy, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins). A final model tested further adjustment for left ventricular ejection fraction. Sensitivity analyses are also shown, including the analysis of complete cases and propensity score-matching (see methods).
